Cyclosporine 0.1% (Ikervis®) as a corticoid-sparing agent in Lyell syndrome with KeraKlear® keratoprosthesis

Miriam Rahhal-Ortuño; Alex-Samir Fernández-Santodomingo; Carla Villena-Alvarado; Emma Marín-Payá; Marina Aguilar-González; Salvador García-Delpech

doi:10.4103/tjo.tjo_1_20

Cyclosporine 0.1% (Ikervis^®) as a corticoid-sparing agent in Lyell syndrome with KeraKlear^® keratoprosthesis

Taiwan J Ophthalmol. 2020 Apr 21;10(4):309-311. doi: 10.4103/tjo.tjo_1_20. eCollection 2020 Oct-Dec.

Authors

Miriam Rahhal-Ortuño¹, Alex-Samir Fernández-Santodomingo¹, Carla Villena-Alvarado¹, Emma Marín-Payá¹, Marina Aguilar-González¹, Salvador García-Delpech¹

Affiliation

¹ Department of Ophthalmology, Hospital Universitari i Politecnic La Fe, Valencia, Spain.

Abstract

Cyclosporine 0.1% was used in a patient with Lyell syndrome, which had undergone a KeraKlear^® keratoprosthesis implant due to the severe ocular involvement to avoid overuse of corticoid agents. To the best of our knowledge, this is the first reported case of cyclosporine 0.1% eye drops to use in Lyell syndrome previously treated with keratoprosthesis implant.

Keywords: Cyclosporine 0.1%; KeraKlear; Lyell syndrome; keratoprosthesis.

Publication types

Case Reports